Literature DB >> 22042038

Aldosterone stimulates nuclear factor-kappa B activity and transcription of intercellular adhesion molecule-1 and connective tissue growth factor in rat mesangial cells via serum- and glucocorticoid-inducible protein kinase-1.

Yoshio Terada1, Satoko Ueda, Kazu Hamada, Yoshiko Shimamura, Koji Ogata, Kosuke Inoue, Yoshinori Taniguchi, Toru Kagawa, Taro Horino, Toshihiro Takao.   

Abstract

Several clinical and experimental data support the hypothesis that aldosterone contributes to the progression of renal injury. To determine the signaling pathway of aldosterone in relation to fibrosis and inflammation in mesangial cells, we investigated the effects of aldosterone on expression and activation of serum- and glucocorticoid-inducible protein kinase-1 (SGK1), the activation of nuclear factor-kappa B (NF-κB activation, and the expressions of intercellular adhesion molecule-1 (ICAM-1) and connective tissue growth factor (CTGF). Aldosterone stimulated SGK1 expression, phosphorylation (Ser-256), and kinase activity. The increments of phosphorylation and expression of SGK1 induced by aldosterone were inhibited by mineralocorticoid receptor (MR) inhibitor (eplerenone). Aldosterone stimulated NF-κB activity measured by NF-κB responsive elements, luciferase assay, and the levels of inhibitor of kappa B (IκB) phosphorylation. This aldosterone-induced activation of NF-κB was inhibited by the transfection of dominant-negative SGK1. Furthermore, aldosterone augmented the promoter activities and protein expressions of ICAM-1 and CTGF. The effects of aldosterone on ICAM-1 and CTGF promoter activities and protein expressions were inhibited by the transfection of dominant-negative SGK1 and dominant-negative IκBα. We also found that the MR antagonist significantly ameliorated the glomerular injury and enhancements in SGK1, ICAM-1, and CTGF expressions induced by 1% sodium chloride and aldosterone in vivo. In conclusion, our findings suggest that aldosterone stimulates ICAM-1 and CTGF transcription via activation of SGK1 and NF-κB, which may be involved in the progression of aldosterone-induced mesangial fibrosis and inflammation. MR antagonists may serve as useful therapeutic targets for the treatment of glomerular inflammatory disease.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22042038     DOI: 10.1007/s10157-011-0498-x

Source DB:  PubMed          Journal:  Clin Exp Nephrol        ISSN: 1342-1751            Impact factor:   2.801


  41 in total

1.  Excessive transcription of the human serum and glucocorticoid dependent kinase hSGK1 in lung fibrosis.

Authors:  Simone Waerntges; Karin Klingel; Cora Weigert; Sophie Fillon; Miriam Buck; Erwin Schleicher; Hans P Rodemann; Cornelius Knabbe; Reinhard Kandolf; Florian Lang
Journal:  Cell Physiol Biochem       Date:  2002

2.  Impaired renal Na(+) retention in the sgk1-knockout mouse.

Authors:  Peer Wulff; Volker Vallon; Dan Yang Huang; Harald Völkl; Fang Yu; Kerstin Richter; Martina Jansen; Michaela Schlünz; Karin Klingel; Johannes Loffing; Gunther Kauselmann; Michael R Bösl; Florian Lang; Dietmar Kuhl
Journal:  J Clin Invest       Date:  2002-11       Impact factor: 14.808

Review 3.  Implications of species difference for clinical investigation: studies on the renin-angiotensin system.

Authors:  N K Hollenberg
Journal:  Hypertension       Date:  2000-01       Impact factor: 10.190

4.  Characterization of sgk, a novel member of the serine/threonine protein kinase gene family which is transcriptionally induced by glucocorticoids and serum.

Authors:  M K Webster; L Goya; Y Ge; A C Maiyar; G L Firestone
Journal:  Mol Cell Biol       Date:  1993-04       Impact factor: 4.272

5.  The serum- and glucocorticoid-induced kinase is a physiological mediator of aldosterone action.

Authors:  A Bhargava; M J Fullerton; K Myles; T M Purdy; J W Funder; D Pearce; T J Cole
Journal:  Endocrinology       Date:  2001-04       Impact factor: 4.736

6.  The PIF-binding pocket in PDK1 is essential for activation of S6K and SGK, but not PKB.

Authors:  R M Biondi; A Kieloch; R A Currie; M Deak; D R Alessi
Journal:  EMBO J       Date:  2001-08-15       Impact factor: 11.598

7.  Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats.

Authors:  R Rocha; P N Chander; K Khanna; A Zuckerman; C T Stier
Journal:  Hypertension       Date:  1998-01       Impact factor: 10.190

8.  Aldosterone stimulates proliferation of mesangial cells by activating mitogen-activated protein kinase 1/2, cyclin D1, and cyclin A.

Authors:  Yoshio Terada; Takahiko Kobayashi; Hitoshi Kuwana; Hiroyuki Tanaka; Seiji Inoshita; Michio Kuwahara; Sei Sasaki
Journal:  J Am Soc Nephrol       Date:  2005-06-23       Impact factor: 10.121

9.  Long-term benefits of angiotensin-converting enzyme inhibitor therapy in patients with severe immunoglobulin a nephropathy: a comparison to patients receiving treatment with other antihypertensive agents and to patients receiving no therapy.

Authors:  D C Cattran; C Greenwood; S Ritchie
Journal:  Am J Kidney Dis       Date:  1994-02       Impact factor: 8.860

10.  Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism.

Authors:  C G Brilla; L S Matsubara; K T Weber
Journal:  J Mol Cell Cardiol       Date:  1993-05       Impact factor: 5.000

View more
  25 in total

1.  Essential role of ICAM-1 in aldosterone-induced atherosclerosis.

Authors:  Vincenzo Marzolla; Andrea Armani; Caterina Mammi; Mary E Moss; Vittoria Pagliarini; Laura Pontecorvo; Antonella Antelmi; Andrea Fabbri; Giuseppe Rosano; Iris Z Jaffe; Massimiliano Caprio
Journal:  Int J Cardiol       Date:  2017-01-05       Impact factor: 4.164

Review 2.  Impact of aldosterone antagonists on the substrate for atrial fibrillation: aldosterone promotes oxidative stress and atrial structural/electrical remodeling.

Authors:  Fadia Mayyas; Karem H Alzoubi; David R Van Wagoner
Journal:  Int J Cardiol       Date:  2013-08-15       Impact factor: 4.164

3.  New roles of aldosterone and mineralocorticoid receptors in cardiovascular disease: translational and sex-specific effects.

Authors:  Ana Paula Davel; Iris Z Jaffe; Rita C Tostes; Frederic Jaisser; Eric J Belin de Chantemèle
Journal:  Am J Physiol Heart Circ Physiol       Date:  2018-06-29       Impact factor: 4.733

4.  Crosstalk between peroxisome proliferator-activated receptor-γ and mineralcorticoid receptor in TNF-α activated renal tubular cell.

Authors:  Jing Xiao; Weijun Chen; Yijun Lu; Xiaoli Zhang; Chensheng Fu; Zhenwen Yan; Zhenxing Zhang; Zhibin Ye
Journal:  Inflamm Res       Date:  2015-06-14       Impact factor: 4.575

5.  A novel mutation of sgk-1 gene in central serous chorioretinopathy.

Authors:  Mahmut Akyol; Muhammet Kazım Erol; Ozdemir Ozdemir; Deniz Turgut Coban; Ahmet Burak Bilgin; Esin Sogutlu Sari; Elif Betul Turkoglu
Journal:  Int J Ophthalmol       Date:  2015-02-18       Impact factor: 1.779

Review 6.  Therapeutic targeting of aldosterone: a novel approach to the treatment of glomerular disease.

Authors:  Andrew S Brem; Rujun Gong
Journal:  Clin Sci (Lond)       Date:  2015-05       Impact factor: 6.124

7.  Mineralocorticoid Receptor (MR) trans-Activation of Inflammatory AP-1 Signaling: DEPENDENCE ON DNA SEQUENCE, MR CONFORMATION, AND AP-1 FAMILY MEMBER EXPRESSION.

Authors:  Edward J Dougherty; Jason M Elinoff; Gabriela A Ferreyra; Angela Hou; Rongman Cai; Junfeng Sun; Kevin P Blaine; Shuibang Wang; Robert L Danner
Journal:  J Biol Chem       Date:  2016-09-20       Impact factor: 5.157

Review 8.  Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis.

Authors:  Nancy J Brown
Journal:  Nat Rev Nephrol       Date:  2013-06-18       Impact factor: 28.314

Review 9.  The Role of the Mineralocorticoid Receptor in Inflammation: Focus on Kidney and Vasculature.

Authors:  Zachary Belden; Jeffrey A Deiuliis; Mirela Dobre; Sanjay Rajagopalan
Journal:  Am J Nephrol       Date:  2017-10-10       Impact factor: 3.754

10.  P-Selectin Glycoprotein Ligand-1 Deficiency Protects Against Aortic Aneurysm Formation Induced by DOCA Plus Salt.

Authors:  Xianxian Wu; Xing Liu; Hang Yang; Qianlong Chen; Na Zhang; Yuhan Li; Xingchen Du; Xue Liu; Xiaoliang Jiang; Yideng Jiang; Zhou Zhou; Zhiwei Yang
Journal:  Cardiovasc Drugs Ther       Date:  2021-01-11       Impact factor: 3.727

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.